Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

P2X7 polymorphism and chronic lymphocytic leukaemia: lack of correlation with incidence, survival and abnormalities of chromosome 12

Abstract

The P2X7 receptor, a plasma membrane ATP-gated ion channel that plays a role in lymphocyte apoptosis, has been suggested as an important contributory factor to the pathogenesis of chronic lymphocytic leukaemia (CLL). The P2X7 gene resides on chromosome 12 and is polymorphic in the population at large (1513A/C) with the A and C alleles encoding fully active and nonfunctional proteins, respectively. We have evaluated the significance of this polymorphism by genotyping 144 patients with CLL and 348 healthy controls using a tetraprimer ARMS assay. We found no significant difference in allele frequency between patients and controls. Although patients with the C allele (A/C heterozygotes or C/C homozygotes) had a marginally shorter survival than those who were homozygous for the A allele, this difference was not significant for either the patient group considered as a whole or for IgVH-mutated/unmutated subsets. Finally, no association was found between trisomy 12 and P2X7 genotype. We conclude that the influence, if any, of P2X7 genotype on susceptibility to CLL or clinical outcome is small.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Rozman C, Montserrat E . Chronic lymphocytic leukemia. N Engl J Med 1995; 333: 1052–1057.

    Article  CAS  PubMed  Google Scholar 

  2. Hamblin T . Chronic lymphocytic leukaemia: one disease or two? Ann Hematol 2002; 81: 299–303.

    Article  CAS  PubMed  Google Scholar 

  3. Wiley JS, Gargett CE, Zhang W, Snook MB, Jamieson GP . Partial agonists and antagonists reveal a second permeability state of human lymphocyte P2Z/P2X7 channel. Am J Physiol 1998; 275: C1224–1231.

    Article  CAS  PubMed  Google Scholar 

  4. Rassendren F, Buell GN, Virginio C, Collo G, North RA, Surprenant A . The permeabilizing ATP receptor, P2X7: cloning and expression of a human cDNA. J Biol Chem 1997; 272: 5482–5486.

    Article  CAS  PubMed  Google Scholar 

  5. Gu BJ, Zhang WY, Worthington RA, Sluyter R, Dao-Ung P, Petrou S et al. A Glu-496 to Ala polymorphism leads to loss of function of human the P2X7 receptor. J Biol Chem 2001; 276: 11135–11142.

    Article  CAS  PubMed  Google Scholar 

  6. Wiley JS, Dao-Ung LP, Gu BJ, Sluyter R, Shemon AN, Li CP et al. A loss-of-function polymorphic mutation in the cytolytic P2X7 receptor gene and chronic lymphocytic leukaemia: a molecular study. Lancet 2002; 359: 1114–1119.

    Article  CAS  PubMed  Google Scholar 

  7. Thunberg U, Tobin G, Johnson A, Soderberg O, Padyukov L, Hultdin M et al. Polymorphism in the P2X7 receptor gene and survival in chronic lymphocytic leukaemia. Lancet 2002; 360: 1935–1939.

    Article  CAS  PubMed  Google Scholar 

  8. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK . Unmutated lgV(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848–1854.

    CAS  PubMed  Google Scholar 

  9. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840–1847.

    CAS  PubMed  Google Scholar 

  10. Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, Ibboston RE et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002; 100: 1177–1184.

    CAS  PubMed  Google Scholar 

  11. Adinolfi E, Melchiorri L, Falzoni S, Chiozzip P, Morelli A, Tieghi A et al. P2X7 receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia. Blood 2002; 99: 706–708.

    Article  CAS  PubMed  Google Scholar 

  12. Brito-Babapulle V, Garcia-Marco J, Maljaie SH, Hiorns L, Coignet L, Conchon M et al. The impact of molecular cytogenetics on chronic lymphoid leukaemia. Acta Haematol 1997; 98: 175–186.

    Article  CAS  PubMed  Google Scholar 

  13. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997.

    CAS  PubMed  Google Scholar 

  14. Ye S, Dhillon S, Ke X, Collins AR, Day IN . An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res 2001; 29: E88–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Mattocks C, Tarpey P, Bobrow M, Whittaker J . Comparative sequence analysis (CSA): a new sequence-based method for the identification and characterization of mutations in DNA. Hum Mutat 2000; 16: 437–443.

    Article  CAS  PubMed  Google Scholar 

  16. Thunberg U, Tobin G, Johnson A, Enblad G, Rosenquist R . P2X7 polymorphism and chronic lymphocytic leukemia (letter). Lancet 2003; 361: 1478–1479.

    Article  Google Scholar 

Download references

Acknowledgements

This study was supported by the Wessex Cancer Trust and the China Scholarship Council. We thank Chris Mattocks for help with comparative sequence analysis.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, L., Ibbotson, R., Orchard, J. et al. P2X7 polymorphism and chronic lymphocytic leukaemia: lack of correlation with incidence, survival and abnormalities of chromosome 12. Leukemia 17, 2097–2100 (2003). https://doi.org/10.1038/sj.leu.2403125

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403125

Keywords

This article is cited by

Search

Quick links